A VELCADE (bortezomib) representative will personally deliver your requested materials to the address that you provide below
This portal is dedicated to you—nurses who treat patients with multiple myeloma.
Here you will find information and resources to help you guide your patients through the treatment journey with VELCADE (bortezomib). You will also learn how to manage and educate your patients, with access to key nursing and patient support tools.
VELCADE (bortezomib) is indicated for the treatment of patients with multiple myeloma. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.
VELCADE is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. VELCADE is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of VELCADE.
VELCADE (bortezomib) is for subcutaneous or IV administration only. Because each route of administration has a different reconstituted concentration, caution should be used when calculating the volume to be administered.
Closely monitor patients receiving VELCADE (bortezomib) in combination with strong CYP3A4 inhibitors. Avoid concomitant use of strong CYP3A4 inducers.